LTR Pharma’s successful results from its pivotal bioequivalence clinical study have been featured in Small Caps, highlighting the positive market response to the announcement.
Journalist Colin Hay wrote:
” LTR Pharma (ASX: LTP) has come out of a trading halt with the announcement of successful results from a pivotal bioequivalence clinical study into a breakthrough treatment for erectile dysfunction (ED).
The company’s share price jumped by 37% after initial results from the study of LTR’s SPONTAN first-in-kind nasal spray treatment found it achieved rapid absorption and faster onset of action compared to well-known oral treatments.”